> Details

Smyth, Lillian M.; Piha-Paul, Sarina A.; Won, Helen H.; Schram, Alison M.; Saura, Cristina; Loi, Sherene; Lu, Janice; Shapiro, Geoffrey I.; Juric, Dejan; Mayer, Ingrid A.; Arteaga, Carlos L.; de la Fuente, Macarena I.; Brufksy, Adam M.; Spanggaard, Iben; Mau-Sørensen, Morten; Arnedos, Monica; Moreno, Victor; Boni, Valentina; Sohn, Joohyuk; Schwartzberg, Lee S.; Gonzàlez-Farré, Xavier; Cervantes, Andrés; Bidard, François-Clement; Gorelick, Alexander N.; [...]

Efficacy and Determinants of Response to HER Kinase Inhibition inHER2-Mutant Metastatic Breast Cancer

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Efficacy and Determinants of Response to HER Kinase Inhibition inHER2-Mutant Metastatic Breast Cancer
  • Contributor: Smyth, Lillian M.; Piha-Paul, Sarina A.; Won, Helen H.; Schram, Alison M.; Saura, Cristina; Loi, Sherene; Lu, Janice; Shapiro, Geoffrey I.; Juric, Dejan; Mayer, Ingrid A.; Arteaga, Carlos L.; de la Fuente, Macarena I.; Brufksy, Adam M.; Spanggaard, Iben; Mau-Sørensen, Morten; Arnedos, Monica; Moreno, Victor; Boni, Valentina; Sohn, Joohyuk; Schwartzberg, Lee S.; Gonzàlez-Farré, Xavier; Cervantes, Andrés; Bidard, François-Clement; Gorelick, Alexander N.; [...]
  • Published: American Association for Cancer Research (AACR), 2020
  • Published in: Cancer Discovery, 10 (2020) 2, Seite 198-213
  • Language: English
  • DOI: 10.1158/2159-8290.cd-19-0966
  • ISSN: 2159-8274; 2159-8290
  • Origination:
  • Footnote:
  • Description: AbstractHER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with HER2-mutant metastatic breast cancer. Overall response rate was similar with or without estrogen receptor (ER) blockade. By comparison, progression-free survival and duration of response appeared longer in ER+ patients receiving combination therapy, although the study was not designed for direct comparison. Preexistent concurrent activating HER2 or HER3 alterations were associated with poor treatment outcome. Similarly, acquisition of multiple HER2-activating events, as well as gatekeeper alterations, were observed at disease progression in a high proportion of patients deriving clinical benefit from neratinib. Collectively, these data define HER2 mutations as a therapeutic target in breast cancer and suggest that coexistence of additional HER signaling alterations may promote both de novo and acquired resistance to neratinib.Significance:HER2 mutations define a targetable breast cancer subset, although sensitivity to irreversible HER kinase inhibition appears to be modified by the presence of concurrent activating genomic events in the pathway. These findings have implications for potential future combinatorial approaches and broader therapeutic development for this genomically defined subset of breast cancer.This article is highlighted in the In This Issue feature, p. 161
  • Access State: Open Access